Under the agreement, Igyxos will utilize Selexis’ proprietary SUREtechnology Platform™ to rapidly develop the research cell banks (RCBs) necessary to advance the program to human trials.
ABSCI CLOSES $15.4 M IN SERIES D FUNDING TO ACCELERATE GROWTH AND SCALE DISRUPTIVE PROTEIN PRINTINGTM TECHNOLOGY, ANNOUNCES EXCLUSIVE CO-MARKETING PARTNERSHIP WITH KBI BIOPHARMA
Receive JSR Life Sciences news on your RSS reader.